GA
TEVA icon

Geneva Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Geneva Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$402K Sell
12,101
-450
-4% -$13.9K 0.01% 552
2017
Q1 		$403K Sell
12,551
-687
-5% -$23.4K 0.01% 541
2016
Q4 		$480K Sell
13,238
-8,444
-39% -$337K 0.01% 488
2016
Q3 		$998K Sell
21,682
-2,083
-9% -$109K 0.02% 318
2016
Q2 		$1.19M Sell
23,765
-8,328
-26% -$443K 0.02% 275
2016
Q1 		$1.72M Buy
32,093
+114
+0.4% +$6.69K 0.03% 212
2015
Q4 		$2.1M Buy
31,979
+19,359
+153% +$1.2M 0.04% 192
2015
Q3 		$713K Sell
12,620
-710
-5% -$46K 0.01% 339
2015
Q2 		$788K Buy
13,330
+119
+0.9% +$7.34K 0.01% 350
2015
Q1 		$823K Sell
13,211
-297
-2% -$17.3K 0.01% 336
2014
Q4 		$777K Sell
13,508
-3,442
-20% -$192K 0.01% 334
2014
Q3 		$911K Buy
16,950
+13
+0.1% +$689 0.02% 323
2014
Q2 		$888K Sell
16,937
-28,615
-63% -$1.46M 0.02% 329
2014
Q1 		$2.41M Buy
45,552
+870
+2% +$40.2K 0.04% 189
2013
Q4 		$1.79M Buy
44,682
+14,250
+47% +$561K 0.03% 169
2013
Q3 		$1.15M Buy
30,432
+14,289
+89% +$557K 0.02% 235
2013
Q2 		$633K Buy
+16,143
New +$629K 0.01% 266

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geneva Advisors's TEVA Position: Q2 2017 in Review

Geneva Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 3.6% in Q2 2017, selling an estimated $13.9K and leaving 12,101 shares worth $402K. The position accounts for 0.01% of the portfolio, ranked #552.

Geneva Advisors first reported a position in TEVA in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.41M in Q1 2014. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Geneva Advisors held 12,101 shares of Teva Pharmaceuticals worth $402K as of Q2 2017.
  • Geneva Advisors sold 450 Teva Pharmaceuticals shares in Q2 2017, an estimated $13.9K.
  • Teva Pharmaceuticals made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #552 holding.
  • Geneva Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • Geneva Advisors's Teva Pharmaceuticals position peaked at $2.41M in Q1 2014.
  • 649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.